Product Images Pemrydi Rtu

This is a description of a medication called PEMRYDI/RTU, which is a pemetrexed injection with a concentration of 10mg/mL. It is prescribed for intravenous infusion only, and because it is a hazardous drug, the unused portion needs to be discarded. Each mL of the medication contains 10mg of pemetrexed, which is equivalent to 12.1mg pemetrexed disodium EXP, hemipentahydrate. The recommended dosage is not stated but is available in the prescribing information. PEMRYDI/RTU is manufactured by Zydus Lifesciences Limited in Ahmedabad, India, and distributed by Amneal Pharmaceuticals LLC in Bridgewater, NJ. The medication needs to be stored between 20°C-25°C (68°F-77°F), and excursions are permitted between 15°C-30°C (59°F-86°F).*

This is a product description for an injectable drug called PEMRYDI/RTU. The drug contains 500 mg of pemetrexed per 50 mL of solution, with each mL containing 10 mg of pemetrexed disodium hemipentahydrate. The drug should be discarded if unused, and should be administered undiluted by a healthcare professional. The drug is hazardous and requires a prescription, with dosage information provided in the prescribing information. The drug should be stored between 0°C to 25°C, with some excursions permitted between 15°C to 30°C. The drug is manufactured by Zydus Lifescences Limited in Ahmedabad, India and distributed by Amneal Pharmaceuticals LLC in Bridgewater.*

The text provides information about a medication called PEMRYDI/RTU (pemetrexed injection) which is given intravenously. It comes in a single-dose vial and should be discarded if unused. The drug is considered hazardous. Each mL of the drug contains 10 mg of pemetrexed. Recommended dosage instructions can be found in the prescribing information. It should be stored at 20°C to 25°C (68°F to 77°F) and can be kept within a range of 15°C to 30°C (59°F to 86°F). The medication is manufactured by Zydus Lifesciences Limited in India and distributed by Amneal Pharmaceuticals LLC in Bridgewater, NJ.*

This is a description of a drug called pemetrexed (equivalent to 12.1 mg pemetrexed disodium) that is administered intravenously and comes in a 10 mg/mL dosage. It is recommended to be stored in a temperature range of 20°C to 25°C with excursions permitted up to 15°C to 30°C. The drug is manufactured by Zydus Lifesciences in Ahmedabad, India, and distributed by Amneal Pharmaceuticals LLC. The recommended dosage is available in the prescribing information and the drug is hazardous and for Rxonly. The neutral code number provided is GUJDRUGS/G/26/1304.*

This is a description for Pemetrexed Injection, a hazardous drug that is used for intravenous infusion purposes only. It comes in a single-dose vial with a concentration of 10mg/mL and is recommended for medical use only as per the prescribing information. Each milliliter of the drug contains 10mg of pemetrexed (equivalent to 12.1mg pemetrexed disodium hemipentahydrate). The drug must be administered undiluted and any unused portion should be discarded. It is manufactured by Zydus Lifesciences Limited in Ahmedabad, India, and distributed by Amneal Pharmaceuticals LLC in Bridgewater, New Jersey. It should be stored at a controlled room temperature between 20°C and 25°C or, with USP Controlled Room temperature excursions permitted at 15°C to 30°C.*

Not available.*

This is a table that compares the survival time of patients who were treated with PEMRYDIRTU + Cisplatin (PC) versus those who had Gemcitabine + Cisplatin (GC) treatment. The table shows the number of patients at risk for both treatments and the number of months survived.*

This appears to be a table or chart with columns labeled "Survival Probability", "Patients at Risk", and two treatment options: "PEMRYDIRTU + Cisplatin (PC)" and "Gemcitabine + Cisplatin (GC)". The first row of numbers may indicate the number of patients at risk for each treatment, while the subsequent rows may show survival times in months and the number of patients surviving at each time point. Without additional context, it is difficult to provide a more specific description of the information presented.*

This table appears to show survival probability and time data for patients in a study. The information is divided into two groups: "PEMRYDIRTU" and "Placebo." The data indicates how many patients were still at risk for each month of the study, and how many patients in each group survived for that time period. The text does not provide any additional information about the study, such as the patients' conditions or the study's purpose.*

This appears to be a table or chart displaying survival probability of patients at risk, divided between two groups or treatments (PEMRYDIRTU, presumably an acronym for each group or treatment, and Placebo). The table shows the number of patients at risk in each group, as well as their survival time measured in months. However, it is difficult to understand the full context or implications of this data without additional information, such as the purpose of the study or the specific treatment being evaluated.*